HIV: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• CCR5 1
• CXCR4 0
• PD-1 2
• IL-15 1
• JAK 1
• STING 0
• GLP-1 2
• IL-17 0
• PD-L1 1
• TNF 0
• IL-6 0
• mTOR 1
• TP53 0
• NLRP3 0
• SGLT2 2
• STAT3 0
• AKT 0
• APOL1 0
• PCSK9 0
• PPAR 0
• CD40 1
• NRF2 0
• PI3K 0
• BCL-2 2
• CD19 1
• ERK 0
• HDAC 0
• HIF-1 0
• APOE 0
• BRD4 0
• FOXP3 0
• HSP90 0
• MAPK 0
• METTL3 0
• AMPK 0
• ATM 0
• BDNF 0
• CD20 0
• CD38 0
• CTNNB1 0
• FLT3 0
• HMGB1 0
• IL-1 0
• MET 0
• NMDA 0
• TIGIT 0
• VEGF 0
• ACE2 0
• ALK 0
• ANGPTL3 0
• AQP4 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CFTR 0
• COX-2 0
• CTLA-4 0
• DPP-4 0
• FTO 0
• G6PD 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Comparative and entangled histories of AIDS care in Austria and Slovenia, 1980s–2000s (AIDScare)

  Universitaet Graz· Graz, Austria· EU contribution €230,185· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Immunometabolic Reprogramming via a Gut-derived Organoid Platform (IRGOP)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Dec 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  BRIDGING RESERVOIR SCIENCE, INTEGRATED DRUG DISCOVERY, BIG DATA ANALYTICS, ARTIFICIAL INTELLIGENCE AND EPIDEMIOLOGY (BRIDGE-HIV)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Netherlands· EU contribution €1,703,400· until Sept 2030· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-CSA

  West African Network of Excellence for TB, AIDS and Malaria (WANETAM-4)

  European & Developing Countries Clinical Trials Partnership· Den Haag, Netherlands· EU contribution €12,751,885· until Jun 2031· 14 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Defining the Landscape of Transcriptional Activity during HIV-1 Infection (DELTA-HIV)

  King's College London· London, United Kingdom· EU contribution €260,348· until May 2028

5 of 25 running projects, newest first. Listed amounts together: €81.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia

  NCT05700630· Masonic Cancer Center, University of Minnesota· Updated 26 Feb 2024

  “Abandoned”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

  NCT04340596· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Interleukin-15 to Promote Post-ART Control of HIV

  NCT07145164· Michael Peluso, MD· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 22
• Organoids 6
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 27
• Gene Expression Profiling 62
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 15
• Exome Sequencing 3
• Proteomics 37
• Metabolomics 33
• Mass Spectrometry 16
• Flow Cytometry 45
• Immunohistochemistry 15
• Xenograft Model Antitumor Assays 3
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 79
• Machine Learning 71
• Deep Learning 21
• Cohort Studies 426
• Genome-Wide Association Study 20

• Emergency Department Management of Body-Fluid Exposures Receiving Human Immunodeficiency Virus Post-Exposure Prophylaxis: Adherence to Australian Guideline Recommendations.

  Emerg Med Australas, Dec 2026

• Weight Trajectories in Virally Suppressed People With HIV Compared With Matched People Without HIV, and Predictors of Weight Gain: A 3-Year Cohort Study From the US TRIO Healthcare Network.

  J Acquir Immune Defic Syndr, Nov 2026

• Integrating HCV Testing and Treatment Into HIV Care: A Cohort Study of the HCV Care Cascade in Southwest China.

  Liver Int, Nov 2026

• Evaluating Associations Between Cumulative Use of Chronic Liver Injury-Inducing Antiretroviral Therapy and Hepatocellular Carcinoma, by Chronic Liver Disease Status.

  J Acquir Immune Defic Syndr, Nov 2026

• Prevalence and Predictors of Abnormal Cervical Cytology Among Women Living With HIV and Without HIV From the MACS/WIHS Combined Cohort Study.

  J Acquir Immune Defic Syndr, Nov 2026

• Comorbidity burden and outcomes with long-acting cabotegravir plus rilpivirine in the RELATIVITY cohort.

  AIDS, Oct 2026

• Real-World Implementation Outcomes of Lenacapavir for HIV Preexposure Prophylaxis: Early Findings From a Multicenter United States Cohort.

  Clin Infect Dis, Oct 2026

• Multimorbidity Trajectories and Hospitalization Risk Among People With HIV in Sub-Saharan Africa: A Longitudinal Analysis From the African Cohort Study.

  Clin Infect Dis, Oct 2026

• Associations between biomarkers and clinical outcome in people hospitalized with HIV: a retrospective cohort.

  Rev Lat Am Enfermagem, Oct 2026

• Understanding viral blips in people with HIV on antiretroviral therapy: a nationwide Swedish cohort study of 4,210 individuals.

  BMC Infect Dis, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.